Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13940797 | 0.82 | CNR2 (0.60) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL13940821 | 0.81 | CNR2 (0.54) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4105426 | 0.81 | CNR2 (0.59) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL13940829 | 0.80 | CNR2 (0.48) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4100947 | 0.80 | CNR2 (0.53) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL13940818 | 0.80 | CNR2 (0.55) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4109192 | 0.80 | CNR2 (0.54) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4096889 | 0.80 | CNR2 (0.47) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL13940826 | 0.79 | CNR2 (0.45) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4095619 | 0.78 | CNR2 (0.45) | CNR2CYP2C9CYP2C19CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007088168-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018128-A1 | Compounds | CNR2, CNR1, TRPV1 | CNR2 1/4885CYP2C9 1492/4885CYP2C19 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.